PFG Investments LLC Sells 107,840 Shares of Tilray Brands, Inc. $TLRY

PFG Investments LLC lessened its holdings in shares of Tilray Brands, Inc. (NASDAQ:TLRY) by 88.5% during the 4th quarter, Holdings Channel reports. The firm owned 14,076 shares of the company’s stock after selling 107,840 shares during the period. PFG Investments LLC’s holdings in Tilray Brands were worth $127,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Silverlake Wealth Management LLC bought a new stake in Tilray Brands during the 3rd quarter valued at approximately $25,000. Oppenheimer & Co. Inc. purchased a new position in Tilray Brands during the 3rd quarter valued at approximately $25,000. Unified Investment Management purchased a new position in Tilray Brands during the 3rd quarter valued at approximately $26,000. Y Intercept Hong Kong Ltd purchased a new position in Tilray Brands during the 3rd quarter valued at approximately $30,000. Finally, HighPoint Advisor Group LLC purchased a new position in Tilray Brands during the 3rd quarter valued at approximately $33,000. Institutional investors own 9.35% of the company’s stock.

Key Headlines Impacting Tilray Brands

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Reports the U.S. Justice Department will loosen cannabis restrictions sparked a sector-wide rally that lifted Tilray shares as investors price in a regulatory catalyst that would expand U.S. market opportunity and margin potential. Curaleaf and More Cannabis Stocks Soar. A Regulatory Breakthrough Is Coming.
• Positive Sentiment: Political momentum also surfaced after reports that former President Trump urged rapid reclassification of cannabis, reinforcing the regulatory narrative and prompting short-term buying and bullish options positioning. Tilray Stock Pops on New Trump-Driven Cannabis Hopes. Should You Chase the Rally?
• Positive Sentiment: Technical and research commentary points to a recovery setup: market write-ups highlight an early breakout and momentum that could carry TLRY higher if regulatory progress continues. Tilray Brands (TLRY) Price Forecast: Cannabis Rescheduling Fuels Recovery
• Positive Sentiment: Unusually large options activity: ~45,077 call contracts were bought (about +89% vs. typical daily call volume), indicating speculative bullish bets that can amplify upside moves in the underlying stock.
• Positive Sentiment: Analyst optimism: Roth Capital published a bullish note suggesting Tilray could rally >40% over 12 months based on improving fundamentals and the regulatory outlook, which can attract momentum and retail interest. 1 Wall Street Analyst Says Tilray Stock Could Jump Over 40%. Should You Believe It?
• Neutral Sentiment: Trading was briefly halted on a LULD (Limit Up/Limit Down) pause around 11:49 AM — a mechanical volatility control that indicates rapid price movement but doesn’t change the underlying drivers. (No external link provided.)
• Negative Sentiment: Insider selling: Director David G. Hopkinson sold 33,556 shares at an average $6.94 on April 21. Insider sales can be interpreted by some investors as a cautionary signal, even though they may be routine or pre-planned. Form 4 — David G. Hopkinson Sale

Insider Transactions at Tilray Brands

In related news, Director David G. Hopkinson sold 33,556 shares of the business’s stock in a transaction on Tuesday, April 21st. The stock was sold at an average price of $6.94, for a total transaction of $232,878.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.84% of the stock is currently owned by insiders.

Tilray Brands Stock Performance

NASDAQ TLRY opened at $7.87 on Thursday. The company has a market cap of $917.24 million, a P/E ratio of -0.58 and a beta of 2.00. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.66 and a current ratio of 2.79. The business’s 50 day moving average price is $7.04 and its 200-day moving average price is $9.53. Tilray Brands, Inc. has a fifty-two week low of $3.51 and a fifty-two week high of $23.20.

Tilray Brands (NASDAQ:TLRY) last released its earnings results on Wednesday, April 1st. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.10). The company had revenue of $206.73 million for the quarter, compared to the consensus estimate of $201.35 million. Tilray Brands had a negative net margin of 156.51% and a negative return on equity of 3.31%. During the same period in the prior year, the firm posted ($0.87) EPS. Sell-side analysts predict that Tilray Brands, Inc. will post -0.55 earnings per share for the current year.

Wall Street Analyst Weigh In

TLRY has been the subject of several research analyst reports. Roth Mkm upgraded Tilray Brands from a “neutral” rating to a “buy” rating and set a $10.00 price target for the company in a report on Thursday, April 2nd. Canaccord Genuity Group assumed coverage on Tilray Brands in a report on Tuesday, January 27th. They set a “hold” rating for the company. ATB Cormark Capital Markets dropped their target price on Tilray Brands from $9.50 to $9.00 and set a “sector perform” rating for the company in a report on Thursday, April 2nd. TD Cowen cut their target price on Tilray Brands from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday, March 30th. Finally, Wall Street Zen raised Tilray Brands from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Three research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Tilray Brands presently has a consensus rating of “Hold” and a consensus price target of $11.50.

Tilray Brands Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.